MaxCyte Inc (MXCT)

0.80 +0.75%

MaxCyte Inc (MXCT) is currently trading at $0.80. This represents a gain of 0.75% from the previous session. With a market capitalization of $0.08B, MXCT is a key component of the Health Care sector. Investors looking to trade MXCT should compare margin rates and options platforms to optimize their portfolio management.

Broker Promotion
Get 15 Free Stocks on Moomoo → T&Cs Apply. Trade MXCT commission-free.
Trading Platform Comparison
Moomoo
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Good for small traders
IBKR
  • Min Deposit: $0
  • Commissions: $0–$0.005/share
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Professional-level tools
Ameritrade
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Strong research tools
Webull
  • Min Deposit: $0
  • Commissions: $0
  • Fractional Shares: ✅
  • Options: ✅
  • Notes: Easy mobile app
AI Market Sentiment

As of today, MaxCyte Inc (MXCT) shows a bullish trend. Analysts are watching the 0.82 level closely.

Fundamentals
Mkt Cap0.08B
P/E Ratio0.0000
Volume1,241,791
Others Watching (By Market Cap)
CDXS
Codexis Inc $2.33
-1.69% AGL
Agilon Health I $0.50
+26.90% OVID
Ovid Therapeuti $1.62
+7.28% EDIT
Editas Medicine $2.13
+0.95% PRLD
Prelude Therape $3.29
+15.03%
60-Day Technical Chart
Advanced Charting

Need more indicators for MXCT? Use the world's #1 platform.

Open MXCT on TradingView →
Charting Platforms
TradingView

Advanced charts & indicators, web & mobile

StockCharts

Technical analysis charts with overlays & indicators

BarCharts

Market data, charts, and technical signals

Finviz

Visual stock charts & heatmaps

Yahoo Finance Charts

Basic interactive charts with indicators

Side-by-Side: Stocks Near $1
Metric MXCT
+0.75% 		ALIT
+2.72% 		BYND
+10.09% 		DVLT
+3.16%
Price $0.80 $0.79 $0.80 $0.72
Mkt Cap $0.08B $0.42B $0.36B $0.42B
- View → View → View →
Latest Headlines
New MaxCyte lab device runs 96 cell samples in a three-minute cycle Stock Titan • Feb 24, 2026 MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio Yahoo Finance • Aug 11, 2025 MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance • Aug 6, 2025 34% Workforce Reduction: MaxCyte's $13.6M Cost-Cutting Plan Aims to Accelerate Path to Profitability Stock Titan • Sep 22, 2025 Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO Business Wire • Dec 1, 2025
● Gemini Agentic AI Analyst Insight for MXCT
Market Education
View All Articles →
External Research